Ansa Biotechnologies
Ansa Biotechnologies is a DNA Synthesis & Biofoundries company founded in 2017 and based in Emeryville, United States.
Ansa Biotechnologies, founded in 2017 and based in Emeryville, California, develops an enzymatic DNA synthesis platform that produces long, complex DNA sequences that stymie legacy chemical methods. In 2025 it raised a $54.4 million oversubscribed Series B led by Cerberus Ventures, and launched a service offering sequence-perfect clonal DNA up to 50 kilobases with turnaround of roughly three to four weeks. Ansa markets an 'On-Time Guarantee'—a complete order delivered on time or it is free—positioning DNA synthesis as a predictable, deadline-driven service. Its scientific co-founders are Dan Lin-Arlow and Sebastian Palluk.
Its enzymatic approach targets the long, hard-to-make DNA constructs that trip up chemical synthesis, and its on-time guarantee reframes synthesis as a reliable industrial service rather than a research gamble.
ansabio.com ↗·DNA Synthesis & Biofoundries·
United States·private 
